NR1H4 and fatty liver disease: To determine whether inhibition of intestinal FXR could be a therapeutic target for HFD-induced obesity, insulin resistance and hepatic steatosis, and to confirm that this transcription factor is a suitable drug target, mice fed a chow diet or a HFD were orally administered with Gly-MCA.